Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;42(3):301-304.
doi: 10.5114/ceji.2017.70974. Epub 2017 Oct 30.

Interference RNA in immune-mediated oral diseases - minireview

Affiliations
Review

Interference RNA in immune-mediated oral diseases - minireview

Raghu Dhanapal et al. Cent Eur J Immunol. 2017.

Abstract

Immune-mediated oral disorders are characterised by their chronicity, and some are refractory to treatment. Interference RNA (iRNA) has been implicated in the underlying mechanism of such immune-mediate oral and refractory inflammatory oral diseases. iRNA-based understanding of the mechanism in these diseases may help to produce non-invasive diagnostic methodologies and treatment modalities of such drug non-responsive diseases. Oral lesions in these immune-mediated diseases can precede the occurrence of lesions in other regions of the body. The early diagnosis and treatment of these drug non-responsive diseases might benefit the patient by reducing chronicity and probably even resolving the disease. This aim of the present minireview is to give an overview of the possible implications of iRNA on the pathogenesis, diagnosis, and treatments of immune-mediated and inflammatory oral diseases. The manuscript can form the framework for research on iRNA in these immune-mediated oral disorders.

Keywords: Immune disorders; RNA interference; RNAi therapies; oral manifestations.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

  • RNA Interference Ex Vivo.
    Liu S. Liu S. Methods Mol Biol. 2024;2766:145-151. doi: 10.1007/978-1-0716-3682-4_15. Methods Mol Biol. 2024. PMID: 38270874

References

    1. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806–811. - PubMed
    1. Hui L, Muller F, George AC. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12:847–865. - PMC - PubMed
    1. Tiemann K, Rossi JJ. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med. 2009;1:142–151. - PMC - PubMed
    1. Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Therapy. 2010;17:523–531. - PubMed
    1. Ranganathan K, Sivasankar V. MicroRNAs-biology and clinical applications. J Oral Maxillofac Pathol. 2014;18:229–234. - PMC - PubMed

LinkOut - more resources